The scientific and technological advent of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is one of the most exciting developments of the past decade, particularly in the field of gene editing. The technology has two essential components, (1) a guide RNA to match a targeted gene, and (2) a CRISPR-associated protein (e.g., Cas 9, Cas12, or Cas13) that acts as an endonuclease to specifically cut DNA. This specificity and reconfigurable nature of CRISPR has also spurred intense academic and commercial interest in the development of CRISPR-based molecular diagnostics. CRISPR Cas12 and Cas13 orthologs are most commonly applied to diagnostics, and these cleave and become activated by DNA and RNA targets, respectively. Despite the resulting intense research activity, the possible limits of detection and applications of CRISP-based diagnostics remain an open question. A major reason for this is that reports of CRISPR-Cas kinetic rates have been widely inconsistent, and the vast majority of these reports have been shown to contain gross errors including violations of basic conservation and kinetic rate laws. It is the intent of this Perspective to bring attention to these issues and to, more importantly, identify potential improvements in the manner in which CRISPR kinetic rates and assay LoDs are reported and compared. The CRISPR field would benefit from formal checks of self-consistency of data, providing sufficient information and raw data such that experiments can be reproduced, and, in the case of publications that report LoDs of novel assays, concurrent and clear reporting of the kinetic rate constants responsible for such LoDs. The early development of CRISPR-based diagnostics calls for self-reflection and urges all of us to proceed with caution.